dilTIAZem HCl 125 mg per 125 mL — Class II drug recall D-0302-2022
Terminated recall by SterRx, LLC, reported 2022-01-05, distributed nationwide. Lack of Assurance of Sterility
| Recall number | D-0302-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | SterRx, LLC, Plattsburgh, NY, United States |
| Recall initiated | 2021-11-12 |
| Classified | 2021-12-29 |
| Reported by FDA | 2022-01-05 |
| Terminated | 2023-12-06 |
| Distributed | Nationwide (US) |
| Quantity | 24,300 bags |
| Reason classes | sterility |
| NDC | 70324-0976-01 |
| Lot numbers | 18-FEV-22, S21164/BTV, S21191/BUU, S21197/BUZ, S21220/BVV, S21271/BX0, S21272/BXP, S21299/BYP, S21300/BYQ |
Product
dilTIAZem HCl 125 mg per 125 mL (1 mg per mL) in 0.7% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY, 12903, NDC 70324-976-01.
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0302-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.